[CAS NO. 1405-87-4] Bacitracin
PRODUCTS SPECIFICATIONS [1405-87-4]
DESCRIPTION [1405-87-4]
Overview
| MDL | MFCD27976769 |
|---|---|
| Molecular Weight | 1422.69 |
| Molecular Formula | C66H103N17O16S |
| SMILES | [Bacitracin] |
Summary
Bacitracin is a polypeptide antibiotic against staphylococcal and pathogenic protozoa infections. Bacitracin inhibits cell wall biosynthesis and permeability through binding to the undecaprenyl pyrophosphate. Bacitracin inhibits macromolecular synthesis. Bacitracin is also a protein disulfide isomerase ( PDI ) inhibitor [1] [2] [3] .
In Vitro
Bacitracin (64 μg/mL, 24 h) together with Colistin shows antibacterial activity against
S. aureus
BA01611
[1]
.
Bacitracin (64 μg/mL, 1 or 2 h) damages the cell surface to grape-like cell clusters, and the cell boundaries are faint and unclear
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Bacitracin (0-100 mg/kg, intramuscular injection, daily for 12 consecutive days) shows anti-tumor efficacy in HCC model
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | HCC model (MH134 cells implanted) [3] |
| Dosage: | 0, 10, 50, and 100 mg/kg |
| Administration: | Intramuscular injection (i.m), daily for 12 consecutive days. |
| Result: |
Decreased tumor volumes.
Decreased the percentage of PDI-stained vascular densities. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00000635 | National Institute of Allergy and Infectious Diseases (NIAID)|Glaxo Wellcome |
Herpes Simplex|HIV Infections
|
Not Applicable | |
| NCT00671541 | Lahey Clinic |
Chronic Sinusitis
|
March 2006 | Phase 4 |
| NCT03213249 | Washington University School of Medicine|The Plastic Surgery Foundation |
Breast Implant Infection|Mammoplasty
|
July 25, 2017 | Phase 1 |
| NCT01516463 | Healthpoint |
Burn, Partial Thickness
|
March 2012 | Phase 4 |
| NCT01668030 | University of Louisville|Healthpoint |
Burns
|
February 2012 | Phase 4 |
| NCT03483363 | The University of Texas Health Science Center, Houston |
Surgical Site Infection
|
October 9, 2018 | Phase 4 |
| NCT02673229 | University of Kansas Medical Center |
Burn, Partial Thickness
|
January 2014 | Phase 4 |
| NCT01350102 | Susan Hassenbein|Milton S. Hershey Medical Center |
Diabetes, Type 1|Diabetes, Type 2|Foot Ulcer, Diabetic
|
February 2012 | Phase 4 |
| NCT00132600 | Mekos Laboratories AS |
Allergic Contact Dermatitis
|
April 2005 | Phase 2 |
| NCT04880655 | University of Tennessee|Medline Industries |
Burns|Partial-thickness Burn
|
August 3, 2021 | Not Applicable |
| NCT01222832 | Steward St. Elizabeth´s Medical Center of Boston, Inc. |
Paranasal Sinus Disease
|
July 2010 | Phase 2 |
| NCT02106962 | California Institute of Renal Research|Imprimis Pharmaceuticals, Inc. |
Arteriovenous Fistula
|
April 2014 | Phase 4 |
| NCT03929224 | Ascension South East Michigan |
Skin Infection
|
October 25, 2018 | Phase 4 |
| NCT01359735 | Healthpoint |
Non-melanoma Skin Cancer
|
May 2011 | Phase 2 |
| NCT03968835 | NYU Langone Health |
Finger Injuries|Amputation, Traumatic
|
December 24, 2018 | |
| NCT00705354 | Lahey Clinic |
Sinusitis|Chronic Sinusitis
|
January 2009 | Not Applicable |
Appearance
Solid
Source
Tracey I strain of Bacillus subtilis
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
H 2 O : 100 mg/mL ( 70.29 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 0.7029 mL | 3.5145 mL | 7.0289 mL |
| 5 mM | 0.1406 mL | 0.7029 mL | 1.4058 mL |
| 10 mM | 0.0703 mL | 0.3514 mL | 0.7029 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (70.29 mM); Suspended solution; Need ultrasonic
References
- [1] Si W, et al. Colistin Induces S. aureus Susceptibility to Bacitracin. Front Microbiol. 2018 Nov 20;9:2805.
- [2] Mohamed Faisal, et al. Bacitracin Inhibits the Oyster Pathogen Perkinsus marinus in Vitro and in Vivo. Journal of Aquatic Animal Health. Volume 11, 1999 - Issue 2.
- [3] Yu SJ, et al. Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition. J Bioenerg Biomembr. 2012 Feb;44(1):101-15.
Synonyms